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Chronic kidney disease (CKD), especially end-stage renal disease (ESRD), is associated with high morbidity and 
mortality due to cardiovascular disease (CVD) and infection, two common complications of ESRD that may be 
related, in part, to chronic inflammation and protein-energy wasting (PEW). Recently, in a Japanese prospective 
cohort study, we reported that there was significantly higher risk for CVD-related events in CKD patients with 
an increased neutrophil/lymphocyte ratio (NLR) at the start of their dialysis therapy. Because higher neutrophil 
count reflects inflammation and lower lymphocyte count may reflect malnutrition, NLR is hypothesized to be a 
more sensitive index than other existing inflammatory markers for detecting those at high risk for CVD-related 
events. This research highlight describes the potentials of NLR as a prognostic marker in patients with CKD. 
Although further studies are required to better understand its value as prognostic tool in clinical practice, 
current data suggest that NLR may be a useful and inexpensive marker for identifying CKD patients at high risk 
for CVD-related complications. 
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Introduction 
Reduced renal function is a significant risk factor for 
mortality in patients with chronic kidney disease (CKD); this 
risk is further increased as CKD progresses to end-stage 
renal disease (ESRD) [1]. The number one cause of death in 
patients with ESRD is cardiovascular disease (CVD) [1], 
while the second cause is infection [2]. Recently, in a 
Japanese prospective cohort study, we reported on the 
association between CVD and the neutrophil/lymphocyte 
ratio (NLR), a new index of inflammation in incident dialysis 
patients [3]. According to 2013 data from the Japanese 
Society of Dialysis Therapy, the total annual death rate in 
Japanese dialysis patients was 9.8%, while CVD and 
infection death rates were 3.8% and 1.96%, respectively [4]. 
The high mortality in this patient population may be related, 
in part, to immune dysfunction due to the uremic milieu [5]. 
CKD has been likened to a clinical model of premature 
ageing [6]. The uremic phenotype is characterized by various 
features of ageing, such as atherosclerosis, protein-energy 
wasting (PEW), oxidative stress, inflammation, sarcopenia, 
osteoporosis, and frailty, which all play a role in the 
increased risk of CVD and infection [7]. Among them, poor 
nutrition status and inflammation are highly prevalent and 
mutually entangled in patients with CKD [8]. The condition of 
poor nutrition status with exhausted body stores of protein 
and energy, now termed as PEW [9], is strongly associated 
with inflammation in patients with CKD [10]. In order to 
establish a new strategy to improve premature mortality in 
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patients with CKD, we started patient-oriented research 
called the Nagoya Immunity System in End-stage renal 
disease (NISE) study, a prospective cohort study of Japanese 
incident dialysis patients that started in 2007. In this research 
highlight, we introduce the backgrounds of our ongoing 
cohort study and discuss the potential role of NLR as an 
inflammatory biomarker in patients with CKD. 
Chronic inflammation and infection in patients with CKD  
In patients with CKD, the most widely studied biomarker 
associated with PEW and inflammation is C-reactive protein 
(CRP) [11, 12]. In CKD, inflammation may be induced by 
multiple causes, including dialysis-related factors such as 
membrane bioincompatibility and back-filtration of 
endotoxins from the dialysate [13], and non–dialysis-related 
factors such as non-access related infections and 
comorbidities [14]. While dialysis techniques have 
progressively developed to decrease dialysis-related risk 
factors, including inflammation [13], the rate of infections has 
not diminished [15]. The infectious disease depends on the 
individual patient’s conditions, including immune 
dysfunction, PEW, comorbid conditions, dental illness, use of 
immunosuppression drugs, and, not least, presence of 
vascular access devices [16]. Central catheter [17, 18], 
periodontal disease [19], and bacterial translocation from the 
gastrointestinal tract [20] are often verified or suspected as a 
cause of chronic low-grade inflammation; however, it is 
likely that many unrecognized subclinical infections with 
opportunistic pathogens also contribute [21]. 
The high prevalence of infections in patients with CKD is 
deplorable, but especially since several kinds of infections, 
such as blood access-related infections and viral hepatitis, 
can be prevented by improving clinical practices. This 
vicious triad of immune dysfunction, infection, and 
inflammation is linked to increased risk for CVD-related 
morbidity and mortality [5]. Indeed, Dalrymple et al. reported 
that during the 30 days following an infection-related 
hospitalization, the risk for a CVD-related event in dialysis 
patients increased by 25% [22]. Furthermore, it was reported 
that cardiac complications worsen the outcomes of 
pneumonia in patients with CKD [23]. We believe that 
decreasing the incidence of infections may promise to 
improve CVD-related events, in part, by controlling 
inflammation.  
Monitoring CRP level is still not routine in many dialysis 
centers worldwide, especially in the USA and Canada while 
the employment of routine measurement of CRP in Japanese 
dialysis center is over 70% [11, 24]. Moreover, baseline CRP 
levels might differ among races [25]. For example, CRP levels 
in Asian patients with CKD, including Japanese, seem to be 
much lower than those in Western patients with CKD [25]. In 
addition, CRP level measured by the standard technique may 
not detect low-grade inflammation, especially in Japanese 
patients with CKD [26]. Procalcitonin (PCT), a precursor of 
calcitonin and a polypeptide of 116 amino acids (molecular 
weight, 13 kDa), is a specific biomarker of bacterial infection 
[27]. Serum PCT (sPCT) has been reported to increase during 
bacterial infections in patients with CKD [28]. Based on data 
from the NISE cohort, we observed that PCT was positively 
correlated with CRP level [29]. In that paper, we also 
demonstrated that global DNA hypermethylation (gene 
expression under control by DNA methylation) was 
associated with inflammatory markers, including ferritin and 
PCT, suggesting that inflammation induced by subclinical 
bacterial infection promotes DNA methylation [29].  
Inflammation and impaired nutrition status including 
PEW 
In the NISE study, we are focusing on nutritional status as 
well as inflammation. The Subjective Global Nutritional 
Assessment (SGA) [30] is a reliable tool for assessing PEW. 
Guidelines released by the National Kidney Foundation’s 
Kidney Disease/Dialysis Outcomes and Quality Initiative in 
2000 recommended use of the SGA for assessing PEW in 
dialysis patients [31]. Thus, we have investigated the SGA as 
well as other markers of nutritional status such as serum 
albumin level in the NISE study.  
There are other composite indices for evaluating nutrition 
state in patients with CKD. The Geriatric Nutritional Risk 
Index (GNRI) was originally developed for elderly patients, 
and is calculated from serum albumin level and body weight 
[32]. Recently, there have been some reports that the GNRI is 
a useful clinical nutritional marker for dialysis patients [33, 34]. 
Malnutrition-Inflammation Score (MIS), another 
increasingly employed composite index, comprises a 
questionnaire similar to that of SGA, as well as comorbid 
conditions, body mass index, albumin level, and transferrin 
level [35]. Amparo et al. reported that a worsening MIS score 
was associated with inflammation and increased mortality 
risk [10]. Whereas these indices appear to be appropriate 
nutritional markers, we often fail to predict outcome by using 
the GNRI, a modified MIS that considers albumin level, or 
serum albumin level alone. We speculate that one reason 
could be that serum albumin levels in patients undergoing 
dialysis therapy are confounded by volume overload and 
anabolic and catabolic processes.  
Nutrition status and inflammation can affect concentration 
and differentiation of leukocytes. Because hematopoietic 
tissue requires a high nutrient supply, nutritional deficiencies 
in protein and calories may alter bone marrow function, 
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causing it to be insufficient to produce lymphocytes [36]. In 
the Dialysis Outcome and Practice Pattern Study, low 
lymphocyte count was significantly associated with mortality 
in 7700 adult hemodialysis patients [37]. Kuwae et al. 
reported that low lymphocyte percentage was associated with 
mortality and hospitalization, and correlated with MIS, in 
maintenance dialysis patients [38]. Therefore, NLR should be 
a suitable screening marker for patients at the start of dialysis 
therapy because it can be easily calculated, adds little or no 
cost, and can enable detection of high-risk patients who 
require further examination. 
Potential role of NLR as an inflammatory biomarker  
In 2014, based on the NISE study, we reported that a 
higher NLR was associated with higher risk of CVD in 86 
incident dialysis patients with a median follow-up of 38.7 
months [3]. The main finding of that study was that a higher 
NLR was associated with increased risk for CVD-related 
events, both in terms of shorter duration from the start of the 
dialysis therapy to the first CVD event and a large number of 
cumulative CVD events during the follow-up time. Moreover, 
patients with higher NLR had increased relative risk of CVD, 
after adjusting for age, sex, and diabetes. When comparing 
the prognostic power for CVD-related events among NLR, 
inflammatory markers (CRP and interleukin-6), and 
nutritional markers (serum albumin and SGA), NLR was the 
superior marker. According to these results, we concluded 
that NLR may be a useful marker for identifying patients at 
high risk of CVD.  
As we mentioned, CKD is a premature ageing disease, a 
category that also includes chronic obstructive pulmonary 
disease (COPD), inflammatory bowel disease, chronic heart 
failure, and autoimmune diseases [6]. A reliable risk 
prediction marker is necessary for any strategy aiming at 
reducing the high premature mortality in these patients, while 
fastness, simplicity, and low cost would be additional 
features requested in the clinical setting. According to our 
experience, NLR is a simple risk prediction marker for 
evaluating the combined impact of both inflammation and 
impaired nutritional status, without needing a special tool or 
technique.  
NLR is being widely used to identify high-risk patients 
with various illnesses, including cancer [39] and CVD [39-42]. 
In our paper, we discussed NLR and clinical outcomes in 
patients with ESRD. Moreover, with regard to patients with 
CKD of other stages, high NLR predict worse outcomes also 
in patients with stage 4 CKD, and faster progression to renal 
replacement therapy [43]. High NLR also is related to 
endothelial dysfunction and increased CVD-related events 
[44].  
Since releasing our report [3], the number of studies on 
NLR has been increasing in the fields of cancer, 
atherosclerotic disease including CVD in CKD patients. In 
2004, Rifaioglu et al. reported that NLR was higher in 
patients with Behçet disease compared with healthy subjects, 
and that increased NLR correlated with disease activity [45]. 
In 2005, it was reported that NLR in patients with ulcerative 
colitis was associated with active phase of the disease [46]. On 
the other hand, although obesity causes subclinical 
inflammation, NLR was not a good indicator of 
inflammation in patients with obesity and metabolic 
syndrome because they showed higher lymphocyte as well as 
leukocyte, neutrophil counts, and CRP level [47]. In addition, 
Salciccioli et al. investigated 5000 patients treated at the 
intensive care unit in a large clinical database, and reported 
that NLR was significantly associated with mortality; 
however, this relationship disappeared in patients with sepsis 
[48]. We speculate that NLR may be superior for identifying 
subclinical inflammation and malnutrition, but further studies 
are required to clarify its indication and limitations. 
Conclusions 
NLR has emerged as a suitable screening marker for 
identifying high-risk patients with chronic inflammatory 
disease including those with CKD. We believe that NLR has 
the potential to become a common biomarker in the clinical 
setting because it is inexpensive and easily performed.  
Acknowledgments 
The basic study of this research highlight was funded by 
the Nagoya University Graduate School of Medicine and was 
supported in part by a Grant-in-Aid for Progressive Renal 
Diseases Research, Research on Rare and Intractable Disease, 
from the Ministry of Health, Labour and Welfare of Japan. 
The Department of Nephrology, Nagoya University Graduate 
School of Medicine, reports receiving research promotion 
grants from Kyowa Hakko Kirin Co., Ltd., Dainippon 
Sumitomo Pharma Co., Ltd., Otsuka Phaemaceutical Co., 
Ltd. and Mochida Phaemaceutical Co., Ltd. However, the 
research topics of these donation grants are not restricted.  
Conflict of interest 
Bengt Lindholm is affiliated with Baxter Healthcare. 
Baxter Novum is the result of a grant from Baxter Healthcare 
to Karolinska Institutet. Other authors declare that they have 
no conflict of interest. 
References 
1. Foley RN. Clinical epidemiology of cardiovascular disease in 
chronic kidney disease. J Ren Care 2010; 36 Suppl: 1:4-8. 
Inflammation & Cell Signaling 2016; 3: e683. doi: 10.14800/ics.683; ©  2016 by Sawako Kato, et al. 
http://www.smartscitech.com/index.php/ics 
 
Page 4 of 5 
 
2. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with 
end-stage renal disease compared with the general population. 
Kidney Int 2000; 58:1758-1764. 
3. Abe T, Kato S, Tsuruta Y, Sugiura S, Katsuno T, Kosugi T, et al. 
Neutrophil/lymphocyte ratio as a predictor of cardiovascular 
events in incident dialysis patients: a Japanese prospective cohort 
study. Clin Exp Nephrol 2015; 19:718-724. 
4. Japanese Society of Dialysis Therapy Web site (in Japanese). 
http://www.jsdt.or.jp 2013;  
5. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, 
Yuzawa Y, et al. Aspects of immune dysfunction in end-stage 
renal disease. Clin J Am Soc Nephrol 2008; 3:1526-1533. 
6. Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. 
Chronic kidney disease and premature ageing. Nat Rev Nephrol 
2014; 10:732-742. 
7. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical 
model of premature aging. Am J Kidney Dis 2013; 62:339-351. 
8. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, 
Berglund L, et al. Strong association between malnutrition, 
inflammation, and atherosclerosis in chronic renal failure. Kidney 
Int 1999; 55:1899-1911. 
9. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, 
Cuppari L, et al. A proposed nomenclature and diagnostic criteria 
for protein-energy wasting in acute and chronic kidney disease. 
Kidney Int 2008; 73:391-398. 
10. Amparo FC, Kamimura MA, Molnar MZ, Cuppari L, Lindholm B, 
Amodeo C, et al. Diagnostic validation and prognostic 
significance of the Malnutrition-Inflammation Score in 
nondialyzed chronic kidney disease patients. Nephrol Dial 
Transplant 2015; 30:821-828. 
11. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring 
of inflammation in patients on dialysis: forewarned is forearmed. 
Nat Rev Nephrol 2011; 7:166-176. 
12. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk 
factor and target for therapy in chronic kidney disease. Curr Opin 
Nephrol Hypertens 2011; 20:662-668. 
13. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid 
quality. Semin Dial 2011; 24:1-4. 
14. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, 
et al. Endotoxemia is related to systemic inflammation and 
atherosclerosis in peritoneal dialysis patients. Clin J Am Soc 
Nephrol 2008; 3:431-436. 
15. Foley RN, Collins AJ. The USRDS: what you need to know about 
what it can and can't tell us about ESRD. Clin J Am Soc Nephrol 
2013; 8:845-851. 
16. Quori A, Baamonde-Laborda E, Garcia-Canton C, Lago-Alonso 
MM, Toledo-Gonzalez A, Monzon-Jimenez E, et al. Surveillance 
for infections and other adverse events in dialysis patients in 
southern Gran Canaria. Nefrologia 2011; 31:457-463. 
17. Yao Q, Axelsson J, Heimburger O, Stenvinkel P, Lindholm B. 
Systemic inflammation in dialysis patients with end-stage renal 
disease: causes and consequences. Minerva Urol Nefrol. 2004; 
56:237-248. 
18. Banerjee T, Kim SJ, Astor B, Shafi T, Coresh J, Powe NR. 
Vascular access type, inflammatory markers, and mortality in 
incident hemodialysis patients: the Choices for Healthy Outcomes 
in Caring for End-Stage Renal Disease (CHOICE) Study. Am J 
Kidney Dis 2014; 64:954-961. 
19. Borawski J, Wilczynska-Borawska M, Stokowska W, Mysliwiec 
M. The periodontal status of pre-dialysis chronic kidney disease 
and maintenance dialysis patients. Nephrol Dial Transplant 2007; 
22:457-464. 
20. Kotanko P, Carter M, Levin NW. Intestinal bacterial microflora--a 
potential source of chronic inflammation in patients with chronic 
kidney disease. Nephrol Dial Transplant 2006; 21:2057-2060. 
21. Cazzavillan S, Ratanarat R, Segala C, Corradi V, de Cal M, Cruz 
D, et al. Inflammation and subclinical infection in chronic kidney 
disease: a molecular approach. Blood purification 2007; 25:69-76. 
22. Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, 
Sarnak MJ, et al. The risk of infection-related hospitalization with 
decreased kidney function. Am J Kidney Dis 2012; 59:356-363. 
23. Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, 
Manresa F, et al. Epidemiology, clinical features and outcomes of 
pneumonia in patients with chronic kidney disease. Nephrol Dial 
Transplant 2011;26:2899-906. 
24. Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, 
Kurokawa K, et al. C-reactive protein and mortality in 
hemodialysis patients: the Dialysis Outcomes and Practice 
Patterns Study (DOPPS). Nephron Clin Pract 2011; 117:c167-178. 
25. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella MC, 
Stenvinkel P. Inflammation, malnutrition and atherosclerosis in 
end-stage renal disease: a global perspective. Blood Purif 2002; 
20:454-458. 
26. Crews DC, Sozio SM, Liu Y, Coresh J, Powe NR. Inflammation 
and the paradox of racial differences in dialysis survival. Journal 
of the American Society of Nephrology : J Am Soc Nephrol 2011; 
22:2279-2286. 
27. Weglohner W, Struck J, Fischer-Schulz C, Morgenthaler NG, Otto 
A, Bohuon C, et al. Isolation and characterization of serum 
procalcitonin from patients with sepsis. Peptides 2001; 
22:2099-2103. 
28. Steinbach G, Bolke E, Grunert A, Storck M, Orth K. Procalcitonin 
in patients with acute and chronic renal insufficiency. Wiener 
klinische Wochenschrift 2004; 116:849-853. 
29. Kato S, Lindholm B, Stenvinkel P, Ekstrom TJ, Luttropp K, 
Yuzawa Y, et al. DNA hypermethylation and inflammatory 
markers in incident Japanese dialysis patients. Nephron Extra 
2012; 2:159-168. 
30. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, 
Mendelson RA, et al. What is subjective global assessment of 
nutritional status? JPEN. Journal of parenteral and enteral nutrition 
1987; 11:8-13. 
31. Clinical practice guidelines for nutrition in chronic renal failure. 
K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 
35:S1-140. 
32. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, 
Nicolis I, et al. Geriatric Nutritional Risk Index: a new index for 
evaluating at-risk elderly medical patients. Am J Clin Nutr 2005; 
82:777-783. 
33. Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, 
Ohkawa S, et al. Simplified nutritional screening tools for patients 
on maintenance hemodialysis. Am J Clin Nutr 2008; 87:106-113. 
Inflammation & Cell Signaling 2016; 3: e683. doi: 10.14800/ics.683; ©  2016 by Sawako Kato, et al. 
http://www.smartscitech.com/index.php/ics 
 
Page 5 of 5 
 
34. Kobayashi I, Ishimura E, Kato Y, Okuno S, Yamamoto T, 
Yamakawa T, et al. Geriatric Nutritional Risk Index, a simplified 
nutritional screening index, is a significant predictor of mortality 
in chronic dialysis patients. Nephrol Dial Transplant 2010; 
25:3361-3365. 
35. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A 
malnutrition-inflammation score is correlated with morbidity and 
mortality in maintenance hemodialysis patients. Am J Kidney Dis 
2001; 38:1251-1263. 
36. Fock RA, Blatt SL, Beutler B, Pereira J, Tsujita M, de Barros FE, 
et al. Study of lymphocyte subpopulations in bone marrow in a 
model of protein-energy malnutrition. Nutrition 2010; 26: 
1021-1028. 
37. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, 
Held PJ, et al. Mortality risk in hemodialysis patients and changes 
in nutritional indicators: DOPPS. Kidney Int 2002; 62:2238-2245. 
38. Kuwae N, Kopple JD, Kalantar-Zadeh K. A low lymphocyte 
percentage is a predictor of mortality and hospitalization in 
hemodialysis patients. Clin Nephrol 2005; 63:22-34. 
39. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, 
Clarke SJ. The systemic inflammation-based 
neutrophil-lymphocyte ratio: experience in patients with cancer. 
Crit Rev Oncol Hematol 2013; 88:218-230. 
40. Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M, 
et al. Neutrophil/lymphocyte ratio is related to the severity of 
coronary artery disease and clinical outcome in patients 
undergoing angiography. Atherosclerosis 2012; 225:456-460. 
41. Shah N, Parikh V, Patel N, Patel N, Badheka A, Deshmukh A, et 
al. Neutrophil lymphocyte ratio significantly improves the 
Framingham risk score in prediction of coronary heart disease 
mortality: Insights from the National Health and Nutrition 
Examination Survey-III. Int J Cardiol 2014; 171:390-397. 
42. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. 
Neutrophil-to-lymphocyte ratio and its association with critical 
limb ischemia in PAOD patients. PLoS One 2013; 8:e56745. 
43. Kocyigit I, Eroglu E, Unal A, Sipahioglu MH, Tokgoz B, Oymak 
O, et al. Role of neutrophil/lymphocyte ratio in prediction of 
disease progression in patients with stage-4 chronic kidney disease. 
J Nephrol 2013; 26:358-365. 
44. Solak Y, Yilmaz MI, Sonmez A, Saglam M, Cakir E, Unal HU, et 
al. Neutrophil to lymphocyte ratio independently predicts 
cardiovascular events in patients with chronic kidney disease. Clin 
Exp Nephrol 2013; 17:532-540. 
45. Rifaioglu EN, Sen BB, Ekiz O, Dogramaci AC. Neutrophil to 
lymphocyte ratio in Behcet's disease as a marker of disease 
activity. Acta Dermatovenerol Alp Pannonica Adriat 2014; 
23:65-67. 
46. Posul E, Yilmaz B, Aktas G, Kurt M. Does 
neutrophil-to-lymphocyte ratio predict active ulcerative colitis? 
Wien Klin Wochenschr 2015; 127:262-265.  
47. Bahadir A, Baltaci D, Turker Y, Turker Y, Iliev D, Ozturk S, et al. 
Is the neutrophil-to-lymphocyte ratio indicative of inflammatory 
state in patients with obesity and metabolic syndrome? Anadolu 
Kardiyol Derg 2015; 15:816-822. 
48. Salciccioli JD, Marshall DC, Pimentel M, Santos MD, Pollard T, 
Celi L, et al. The association between the neutrophil-to- 
lymphocyte ratio and mortality in critical illness: an observational 
cohort study. Crit Care 2015; 19:13. 
